Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 19/20 | 0.53 |
| ▸ | ACACA | Q13085 | 19/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12510672 | 0.90 | ACACB (0.58) | ACACBACACAKDM4ECYP1A2CYP3A4 | |
| SCHEMBL12432101 | 0.88 | ACACB (0.56) | ACACBACACAKDM4ECYP1A2CYP3A4 | |
| SCHEMBL12432163 | 0.88 | ACACB (0.52) | ACACBACACA | |
| SCHEMBL12432147 | 0.87 | ACACB (0.55) | ACACBACACAKDM4ECYP1A2CYP3A4 | |
| SCHEMBL12432136 | 0.87 | ACACB (0.56) | ACACBACACAKDM4ECYP1A2CYP3A4 | |
| SCHEMBL12432168 | 0.86 | ACACB (0.56) | ACACBACACA | |
| SCHEMBL2208717 | 0.85 | ACACB (0.53) | ACACBACACAKDM4ECYP1A2CYP3A4 | |
| SCHEMBL12432157 | 0.81 | ACACB (0.52) | ACACBACACA | |
| SCHEMBL2208719 | 0.81 | ACACB (0.49) | ACACBACACAKDM4ECYP1A2CYP3A4 | |
| SCHEMBL2208181 | 0.80 | ACACB (0.43) | ACACBACACAKDM4ECYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7981904-B2 | Acetyl CoA carboxylase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-07-19 | — | — | US | disclosed |
| US-7981904-B2 | Acetyl CoA carboxylase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-07-19 | — | — | US | disclosed |
| US-20090253725-A1 | ACETYL CoA CARBOXYLASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-08 | — | — | US | disclosed |
| US-20090253725-A1 | ACETYL CoA CARBOXYLASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253725-A1 | ACETYL CoA CARBOXYLASE INHIBITORS | ACACA, ACACB, ACAT1 | ACACB 2/4885ACACA 1/4885KDM4E 1756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.